SeaStar Medical Holding Corporation (ICU)
NASDAQ: ICU · Real-Time Price · USD
4.920
-0.150 (-2.96%)
At close: Sep 18, 2024, 4:00 PM
4.800
-0.120 (-2.44%)
After-hours: Sep 18, 2024, 4:09 PM EDT
Company Description
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.
The company offers inflammatory response to fend off infections and repair damaged tissue in the body.
It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.
The company is headquartered in Denver, Colorado.
SeaStar Medical Holding Corporation
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Eric Schlorff |
Contact Details
Address: 3513 Brighton Boulevard, Suite 410 Denver, Colorado 80216 United States | |
| Phone | 844 427 8100 |
| Website | seastarmedical.com |
Stock Details
| Ticker Symbol | ICU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001831868 |
| CUSIP Number | 81256L104 |
| ISIN Number | US81256L1044 |
| Employer ID | 85-3681132 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Eric Schlorff | Chief Executive Officer, President and Executive Director |
| Colonel Kevin Chung FACP, M.D. | Chief Medical Officer |
| Dr. H. David Humes M.D. | Co-Founder and Managing Director |
| David A. Green CPA, M.B.A. | Chief Financial Officer |
| Tom Mullen | Vice President of Operations and Product Development |
| Tim Varacek | Senior Vice President of Commercial and Business Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 27, 2024 | EFFECT | Notice of Effectiveness |
| Aug 27, 2024 | EFFECT | Notice of Effectiveness |
| Aug 21, 2024 | 8-K | Current Report |
| Aug 21, 2024 | 424B5 | Filing |
| Aug 16, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Aug 16, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Aug 13, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Aug 2, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 26, 2024 | D | Notice of Exempt Offering of Securities |